The information that we have about the effectiveness of PrEP in reducing the risk of HIV infection comes from five large-scale studies. Each of these studies was a randomized controlled trial (or RCT), which means that participants in these studies were randomly assigned (like the flip of a coin) to receive either the active PrEP medication (Truvada) or a placebo (a sugar pill). In all of these studies, all participants were also given condoms and risk-reduction counseling about HIV prevention.
|
Name
(location) |
Participants | Results |
|
|---|---|---|---|
|
iPrEx
(Brazil, Ecuador, Peru, South Africa, Thailand, and the United States) |
2,499 MSM and transwomen | 90% fewer HIV infections for those who took the PrEP meds regularly; 44% fewer overall |
|
|
Partners PrEP
(Kenya and Uganda) |
4,747 heterosexual men and women with HIV+ partners | 86-90% fewer infections for those who took the PrEP meds regularly; 75% fewer overall |
|
|
TDF2 Study
(Botswana) |
1,219 heterosexual men and women | 78% fewer HIV infections for those who took their PrEP meds regularly; 63% fewer overall |
|
|
FEM-PrEP
(Kenya, South Africa, and Tanzania) |
2,120 women | No difference; however, less than 35% of women took the PrEP meds they were given |
|
|
VOICE
(South Africa, Uganda, and Zimbabwe) |
5,029 women | No difference; however, less than 30% of women took the PrEP meds they were given |
|
© 2014 HART